Jeffrey L Cummings

Summary

Publications

  1. ncbi Toward a molecular neuropsychiatry of neurodegenerative diseases
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Ann Neurol 54:147-54. 2003
  2. ncbi 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine UCLA, CA, USA
    Brain 129:2867-73. 2006
  3. ncbi Structural correlates of apathy in Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, Laboratory of Neuro Imaging, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Dement Geriatr Cogn Disord 24:91-7. 2007
  4. pmc Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study
    Liana G Apostolova
    Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 27:174-81. 2013
  5. pmc Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 33:1-5. 2012
  6. pmc 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Neurobiol Aging 31:1284-303. 2010
  7. pmc Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Neuroimage 51:488-99. 2010
  8. pmc Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 10911 Weyburn Avenue, Los Angeles, CA 90095, USA
    Mol Imaging Biol 12:218-24. 2010
  9. pmc Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease
    Liana G Apostolova
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 32:118-25. 2011
  10. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010

Detail Information

Publications109 found, 100 shown here

  1. ncbi Toward a molecular neuropsychiatry of neurodegenerative diseases
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Ann Neurol 54:147-54. 2003
    ....
  2. ncbi 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine UCLA, CA, USA
    Brain 129:2867-73. 2006
    ..Novel hippocampal analytic techniques that can track the spread of hippocampal pathology in 3D with such precision are a promising research tool...
  3. ncbi Structural correlates of apathy in Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, Laboratory of Neuro Imaging, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Dement Geriatr Cogn Disord 24:91-7. 2007
    ..Apathy is the most common noncognitive symptom in Alzheimer's disease (AD). The structural correlates of apathy in AD have not yet been described...
  4. pmc Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study
    Liana G Apostolova
    Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 27:174-81. 2013
    ..After correction for baseline hippocampal volume, decline in ADL showed a significant association with right frontal horn enlargement. Executive decline was associated with right frontal and left temporal horn enlargement...
  5. pmc Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 33:1-5. 2012
    ..Changes in cerebrospinal fluid (CSF) levels of 42-amino-acid β-amyloid (Aβ(42)), total tau protein (t-tau) and phosphorylated tau at residue 181 (p-tau(181)) during this state are incompletely characterized...
  6. pmc 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Neurobiol Aging 31:1284-303. 2010
    ..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy...
  7. pmc Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Neuroimage 51:488-99. 2010
    ..After controlling for baseline hippocampal atrophy, memory performance showed regionally specific associations with hippocampal radial distance in predominantly CA1 but also in subicular distribution...
  8. pmc Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 10911 Weyburn Avenue, Los Angeles, CA 90095, USA
    Mol Imaging Biol 12:218-24. 2010
    ..The aim of this study was to investigate the longitudinal positron emission tomography (PET) metabolic changes in the elderly...
  9. pmc Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease
    Liana G Apostolova
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 32:118-25. 2011
    ..Both familial and sporadic Alzheimer's disease (AD) result in progressive cortical and subcortical atrophy. Familial autosomal dominant AD (FAD) allows us to study AD brain changes presymptomatically...
  10. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  11. pmc 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Brain Lang 104:33-41. 2008
    ..Using a novel 3D mapping technique, we demonstrated that in AD language abilities are strongly influenced by the integrity of the perisylvian cortical regions...
  12. pmc Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease
    MEREDITH N BRASKIE
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California Laboratory of Neuro Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California
    Hum Brain Mapp 34:3308-19. 2013
    ..Poorer performing carriers showed greater retrieval period signal, including in the frontal and temporal lobes, suggesting underlying pathological processes...
  13. pmc Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095, USA
    Arch Neurol 69:757-64. 2012
    ..To study the effect of familial Alzheimer disease (FAD) mutations and APOE genotype on plasma signaling protein levels...
  14. ncbi Current and emerging pharmacological treatment options for dementia
    John M Ringman
    Department of Neurology, Alzheimer s Disease Research Center, University of California, Los Angeles, CA 90095 1769, USA
    Behav Neurol 17:5-16. 2006
    ..Their clinical utility is controversial. Many novel approaches that promise to provide more effective treatments are currently being pursued...
  15. ncbi Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 67:57-63. 2006
    ..To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)...
  16. ncbi Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia
    George Bartzokis
    Department of Neurology, The David Geffen School of Medicine at UCLA, USA
    Arch Gen Psychiatry 63:63-72. 2006
    ..This may result in a progressive "disconnection" of widely distributed neural networks that may underlie the age risk factor for AD...
  17. ncbi Early-onset Alzheimer's disease is associated with greater pathologic burden
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Geriatr Psychiatry Neurol 20:29-33. 2007
    ..This suggests that late-onset AD patients have less cognitive reserve than early-onset patients and require fewer pathologic changes to exhibit cognitive deterioration...
  18. pmc Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, 10911 Westwood Blvd, Second Floor, Los Angeles, CA 90095, USA
    Arch Neurol 64:1489-95. 2007
    ..Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy...
  19. pmc Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
    Joshua D Grill
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Neurobiol Aging 34:62-72. 2013
    ..For MCI, the Clinical Dementia Rating scale sum of boxes consistently required the smallest sample sizes. We conclude that predementia clinical trial conduct in Alzheimer's disease is enhanced by the use of biomarker inclusion criteria...
  20. pmc Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  21. pmc Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cereb Cortex 21:877-83. 2011
    ..Our findings of increased fMRI activation associated with APOE genotype but not with FAD mutations suggest that APOE exerts an effect on the BOLD signal that is not readily explained as a compensatory phenomenon...
  22. ncbi 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 20:224-31. 2006
    ..As a global cognitive measure, MMSE depends on the integrity of widely distributed cortical areas in both brain hemispheres with left-sided predominance...
  23. pmc Increased fMRI signal with age in familial Alzheimer's disease mutation carriers
    MEREDITH N BRASKIE
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurobiol Aging 33:424.e11-21. 2012
    ..This suggests that during novelty encoding, increased fMRI activity in the temporal lobe may relate to incipient AD processes...
  24. ncbi Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 24:253-9. 2007
    ..Depression and apathy may identify a subset of MCI subjects at higher risk of progression to Alzheimer's disease (AD). However, it remains uncertain whether a broader spectrum of psychopathology is associated with progression to AD...
  25. ncbi Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 29:406-12. 2010
    ..This was a hypothesis-forming study, designed to provide a basis for possible future research...
  26. pmc Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, University of California at Los Angeles, Los Angeles, CA 90095 7334, USA
    Dement Geriatr Cogn Disord 33:219-25. 2012
    ..We asked if consequently, oxidation of methionine residues to methionine sulfoxide (MetO) was increased in plasma proteins of persons carrying familial AD (FAD) mutations...
  27. pmc Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Associate Clinical Professor, UCLA Department of Neurology, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
    Curr Alzheimer Res 6:341-6. 2009
    ..The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria...
  28. ncbi Neuropathologic correlates of activities of daily living in Alzheimer disease
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:56-9. 2006
    ..Deteriorating activities of daily living in Alzheimer Disease subjects correlate with greater overall pathologic burden and possibly selectively with involvement of the medial temporal, occipital, and orbital frontal regions...
  29. pmc Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment
    Edmond Teng
    Neurobehavior Unit, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Dement Geriatr Cogn Disord 30:189-97. 2010
    ..We explored the relationship between these factors by comparing instrumental activities of daily living (IADLs) among cognitive subtypes of MCI and examining associations between IADL and neuropsychological indices...
  30. ncbi Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations
    John M Ringman
    UCLA Department of Neurology, Alzheimer s Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Brain 130:1767-76. 2007
    ..Decreased FA in of the columns of the fornix is particularly robust in early FAD and may provide a biomarker for early disease in sporadic Alzheimer's disease...
  31. ncbi Positron emission tomography metabolic correlates of apathy in Alzheimer disease
    Gad A Marshall
    Department of Neurology, University of California, Los Angeles, CA, USA
    Arch Neurol 64:1015-20. 2007
    ....
  32. ncbi ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
    ..Experimental behavioral measures were included in the protocol to examine this hypothesis...
  33. doi Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers
    John M Ringman
    Alzheimer s Disease Research Center, UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 25:380-4. 2008
    ..In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs)...
  34. ncbi Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Am J Geriatr Psychiatry 14:605-12. 2006
    ..The authors report the effects of donepezil on behavioral disturbances in patients with relatively severe psychopathology at baseline...
  35. ncbi Reviewing the role of donepezil in the treatment of Alzheimer's disease
    Rachelle S Doody
    Department of Neurology, Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 07730, USA
    Curr Alzheimer Res 9:773-81. 2012
    ....
  36. ncbi Deficits in facial emotion processing in mild cognitive impairment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 23:271-9. 2007
    ..Patients with Alzheimer disease consistently demonstrate impaired performance on tests of facial emotion processing. However, it remains unclear how early in the neurodegenerative process these deficits emerge...
  37. pmc Persistence of neuropsychological testing deficits in mild cognitive impairment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 28:168-78. 2009
    ....
  38. ncbi Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps
    Liana G Apostolova
    Laboratory of Neuro Imaging, Department of Neurology, The David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA
    Arch Neurol 63:693-9. 2006
    ..While most patients with mild cognitive impairment (MCI) transition to Alzheimer disease (AD), others develop non-AD dementia, remain in the MCI state, or improve...
  39. ncbi Dementia with parkinsonism: what is the diagnosis?
    Mei S Chong
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:41-4. 2004
    ..The 72-year-old patient whose case is reviewed here had abnormalities in all three domains...
  40. doi Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Clin Drug Investig 30:41-9. 2010
    ..The aim of the component of the trial reported here was to evaluate the skin tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate AD...
  41. ncbi Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies
    Jeffrey L Cummings
    Departmentsof Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 4:57-62. 2007
    ..Therapeutic regimens for the treatment of AD will include both disease-modifying and symptomatic agents...
  42. pmc Association of GSK3B with Alzheimer disease and frontotemporal dementia
    Barbara A J Schaffer
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, 2506 Gonda, 695 Charles E Young Dr S, Los Angeles, CA 90095 1761, USA
    Arch Neurol 65:1368-74. 2008
    ..As a known tau kinase, GSK3B is a promising candidate gene in the remaining cases of FTD and in AD, for which tau mutations have not been found...
  43. pmc Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, California, USA
    Mov Disord 25:687-95. 2010
    ..Cognitive decline in PD is associated with anterior caudate atrophy and ventricular enlargement...
  44. pmc Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095, USA
    Arch Neurol 69:96-104. 2012
    ..To identify cerebrospinal fluid (CSF) protein changes in persons who will develop familial Alzheimer disease (FAD) due to PSEN1 and APP mutations, using unbiased proteomics...
  45. ncbi Dementia with parkinsonism
    Mei S Chong
    Department of Neurology, The David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:97-101. 2004
  46. ncbi Treatment of Alzheimer's disease: current and future therapeutic approaches
    Jeffrey L Cummings
    Department of Neurology, University of California, The David Geffen School of Medicine, Los Angeles, CA, USA
    Rev Neurol Dis 1:60-9. 2004
    ..Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD...
  47. doi Defining and labeling disease-modifying treatments for Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 5:406-18. 2009
    ..Prevention claims will depend heavily on biomarker outcomes...
  48. ncbi Disease-modifying therapies for Alzheimer disease: challenges to early intervention
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:1622-34. 2007
    ..The neurologic health of the growing aging population demands disease-modifying therapies and the development of methods to identify and test promising candidate agents...
  49. ncbi Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease
    Jeffrey L Cummings
    UCLA Alzheimer s Disease Research Center, University of California, Los Angeles, CA, USA
    CNS Spectr 13:1-20; quiz 22. 2008
    ..Debra Cherry, PhD, discusses the advocacy needs of Alzheimer's disease patients and their caregivers. In addition, Patricia Utermohlen, MA, provides a testimonial of the impact of Alzheimer's disease on an accomplished artist...
  50. ncbi Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
    Po H Lu
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Arch Neurol 63:177-85. 2006
    ..There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD)...
  51. doi Behavioral effects of current Alzheimer's disease treatments: a descriptive review
    Jeffrey L Cummings
    UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:49-60. 2008
    ....
  52. pmc The "Alzheimer's type" profile of semantic clustering in amnestic mild cognitive impairment
    Paula M McLaughlin
    1 Department of Neurology, University of California, Los Angeles, Los Angeles, California
    J Int Neuropsychol Soc 20:402-12. 2014
    ..These findings show that the ability to engage in an effective memory strategy is compromised in aMCI, before AD has developed, suggesting that disruptions in semantic networks are an early marker of the disease. (JINS, 2014, 20, 1-11). ..
  53. ncbi Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, USA
    Dement Geriatr Cogn Disord 25:115-26. 2008
    ..MCI is an important risk state for dementia. Neuropsychiatric symptoms may be present in MCI...
  54. doi Optimizing phase II of drug development for disease-modifying compounds
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:S15-20. 2008
    ..been validated in a successful drug development program; all have some promise for reforming phase II and answering the central question of "how much information is sufficient to proceed to phase III without excessive risk for failure?"..
  55. doi Current therapeutic targets for the treatment of Alzheimer's disease
    Joshua D Grill
    Mary S Easton Center for Alzheimer s Disease Research, Deane F Johnson Center for Neurotherapeutics, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Expert Rev Neurother 10:711-28. 2010
    ..We provide a review of these targets for drug development...
  56. ncbi Regression to the mean: implications for clinical trials of psychotropic agents in dementia
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Curr Alzheimer Res 1:323-8. 2004
    ..Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials...
  57. ncbi Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study
    Jeffrey L Cummings
    University of California, Los Angeles, Alzheimer s Disease Center, Los Angeles, California 90095 1769, USA
    Am J Geriatr Pharmacother 3:137-48. 2005
    ....
  58. ncbi Effective pharmacologic management of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Am J Med 120:388-97. 2007
    ....
  59. ncbi Neuropathologic correlates of apathy in Alzheimer's disease
    Gad A Marshall
    Department of Neurology, University of California at Los Angeles, Reed Neurological Research Center, 2 238, 710 Westwood Plaza, CA 90095 1769, USA
    Dement Geriatr Cogn Disord 21:144-7. 2006
    ..01, and r = 0.438, p = 0.032). This analysis suggests that chronic apathy in AD correlates with a greater anterior cingulate NFT burden and that chronic behavioral changes are more reflective than acute changes of disease pathology...
  60. ncbi Clinical evaluation as a biomarker for Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, Alzheimer s Disease Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    J Alzheimers Dis 8:327-37. 2005
    ..Biomarkers must closely reflect clinical outcomes to be useful as evaluations of disease progression or as outcomes in clinical trials...
  61. pmc Controversies in Alzheimer's disease drug development
    Jeffrey L Cummings
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int Rev Psychiatry 20:389-95. 2008
    ..The questions surrounding these issues must be resolved as disease-modifying therapies for AD are advanced. These controversies are framed and potential directions towards resolution described...
  62. ncbi Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease
    George Bartzokis
    Department of Neurology, Univeristy of California School of Medicine, Los Angeles, CA 90095, USA
    Neurobiol Aging 25:843-51. 2004
    ..In AD this process is globally exacerbated, consistent with an extracellular deleterious process such as amyloid beta-peptide toxicity. Non-invasive measures such as R2 may be useful in primary prevention studies of AD...
  63. ncbi Reconsidering diagnostic criteria for dementia with lewy bodies. Highlights from the Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia, September 17-20, 2003, Newcastle Upon Tyne, United Kingdom
    Jeffrey L Cummings
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:31-4. 2004
  64. ncbi Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies
    Jeffrey L Cummings
    Department of Neurology, 710 Westwood Plaza, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Nat Rev Drug Discov 5:64-74. 2006
    ....
  65. ncbi Behavioral and neuropsychiatric outcomes in Alzheimer's disease
    Jeffrey L Cummings
    Alzheimer s Disease Research Center, Department of Neurology, University of California Los Angeles, 710 Westwood Plaza Rm 2 238, Los Angeles, CA 90095, USA
    CNS Spectr 10:22-5. 2005
    ....
  66. pmc Serotonin 1A receptors in the living brain of Alzheimer's disease patients
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 103:702-7. 2006
    ....
  67. ncbi Dementia with lewy bodies: molecular pathogenesis and implications for classification
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Geriatr Psychiatry Neurol 17:112-9. 2004
    ..Classification systems based on symptom complexes related to the presence of protein misfolding will assist therapeutic decisions...
  68. pmc Integrating ADNI results into Alzheimer's disease drug development programs
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, United States
    Neurobiol Aging 31:1481-92. 2010
    ....
  69. ncbi Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms
    Tzung J Hwang
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 18:17-21. 2004
    ..Psychotic symptoms are significantly more common in the early stage of AD than in MCI. These results are derived from a limited clinical sample and require confirmation in longitudinal community-based investigations...
  70. ncbi Workshop reports from the third Asia-pacific regional meeting of the international working group on harmonization of dementia drug guidelines
    John C Morris
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 20:313. 2006
  71. pmc A potential role of the curry spice curcumin in Alzheimer's disease
    John M Ringman
    University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
    Curr Alzheimer Res 2:131-6. 2005
    ..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology...
  72. ncbi Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease
    Frederic Assal
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, Calif, USA
    Arch Neurol 61:1249-53. 2004
    ..Neuropsychiatric symptoms have been associated with polymorphisms of the promoter region (5-HTTPR ) and intron 2 of the serotonin transporter gene (5-HTTVNTR) or the 5-HT2A and 5-HT2C receptor genes in some but not all studies...
  73. ncbi Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases
    George Bartzokis
    Department of Neurology, UCLA, Los Angeles, California, USA
    Ann N Y Acad Sci 1012:224-36. 2004
    ..In vivo MRI can measure and track brain ferritin iron levels and provides an opportunity to design therapeutic interventions that target high-risk populations early in the course of illness, possibly even before symptoms appear...
  74. ncbi Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease
    Zakiya J Wynn
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Dement Geriatr Cogn Disord 17:100-8. 2004
    ..This effect is believed to be beneficial in improving or stabilizing many behavioral symptoms of AD. Preliminary studies of ChE-Is have shown mixed results; however, the results of more recent studies have been favorable...
  75. pmc Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative
    Jeffrey L Cummings
    Department of Neurology, The Mary S Easton Center for Alzheimer s Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Alzheimers Dis 19:375-88. 2010
    ..The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research...
  76. ncbi Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations
    Jeffrey L Cummings
    Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Am J Geriatr Psychiatry 11:131-45. 2003
    ..Clinical-trial populations differ substantially from unselected populations of AD patients, and these selection biases demand that efficacy data from clinical trials be generalized with caution...
  77. ncbi Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    N Engl J Med 351:56-67. 2004
  78. ncbi Apathy and executive function in Alzheimer's disease
    Susan McPherson
    Alzheimer s Disease Center, Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095 1769, USA
    J Int Neuropsychol Soc 8:373-81. 2002
    ..Neuropsychological measures not dependent on executive functions were unrelated to apathy. Apathy is associated with executive dysfunction and not with other neuropsychological deficits. Apathy is distinct from dysphoria...
  79. ncbi Alzheimer disease
    Jeffrey L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    JAMA 287:2335-8. 2002
  80. ncbi Guidelines for managing Alzheimer's disease: part I. Assessment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2263-72. 2002
    ..Suggestions for easily administered and scored assessment tools are provided, and practical tips are given for supporting primary caregivers, thereby increasing efficiency and quality of care for patients with Alzheimer's disease...
  81. ncbi Guidelines for managing Alzheimer's disease: Part II. Treatment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2525-34. 2002
    ..Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease...
  82. ncbi Neuropsychiatric symptoms in the dementias
    Frederic Assal
    UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Curr Opin Neurol 15:445-50. 2002
    ..Neuropsychiatric, or non-cognitive symptoms are increasingly recognized as manifestations of dementias...
  83. ncbi Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, USA
    Am J Psychiatry 160:341-9. 2003
    ..In this study the authors examined the relationship between delusional thoughts and regional cortical metabolism in patients with Alzheimer's disease...
  84. ncbi Alzheimer's disease: from molecular biology to neuropsychiatry
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Semin Clin Neuropsychiatry 8:31-6. 2003
    ..The steps of the amyloid cascade present multiple targets for drug development and identification of effective disease-modifying anti-Alzheimer's disease treatments...
  85. ncbi Speech and language in progressive nonfluent aphasia compared with early Alzheimer's disease
    Mario F Mendez
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, USA
    Neurology 61:1108-13. 2003
    ..The differentiation of PA from early Alzheimer's disease (AD) is important, given the presence of early language changes in AD...
  86. ncbi Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles 90095 1769, USA
    Am J Psychiatry 161:532-8. 2004
    ....
  87. ncbi Relational integration and executive function in Alzheimer's disease
    James A Waltz
    Departjment of Psychology, University of California, Los Angeles, CA 90095 1563, USA
    Neuropsychology 18:296-305. 2004
    ....
  88. ncbi Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias
    Verna R Porter
    Department of Neurology, University of California, Los Angeles, School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 15:180-6. 2003
    ..These data suggest that anxiety is common among patients with diverse forms of dementia. In AD, anxiety is most common in those with more severe cognitive deterioration and an earlier age at onset...
  89. ncbi The one-minute mental status examination
    Jeffrey L Cummings
    Neurology 62:534-5. 2004
  90. ncbi Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association
    Donald R Royall
    The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Neuropsychiatry Clin Neurosci 14:377-405. 2002
    ..The prevalence and severity of ECF deficits in many disorders remain to be determined, and treatment has been attempted in only a few disorders. Much more research in these areas is necessary...
  91. ncbi Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach
    Rochelle E Tractenberg
    Department of Biomathematics and Biostatistics, Georgetown University School of Medicine, 7 East Main, M702, Georgetown University Hospital, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Neuropsychiatry Clin Neurosci 17:51-60. 2005
    ..Cognitive and functional subscores for the CDR were supported. These findings suggest that changes in behavior and cognition in dementia may have distinct pathophysiologies...
  92. ncbi Neuropsychiatric symptoms and quality of life in Alzheimer disease
    Il Seon Shin
    Department of Psychiatry, Chonnam National University Medical School, Kwangju, Republic of Korea
    Am J Geriatr Psychiatry 13:469-74. 2005
    ..Authors examined the impact of neuropsychiatric symptoms in Alzheimer disease (AD) patients' and caregivers' quality of life (QOL) and assessed the relationship of caregiver distress to neuropsychiatric symptoms and caregiver QOL...
  93. ncbi Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease
    Freddy Ortiz
    The Neuropsychiatry Research Memory Clinic, Olive View UCLA Medical Center, Sylmar, CA 91342, USA
    Am J Alzheimers Dis Other Demen 21:263-73. 2006
    ..These findings have implications for differential sociocultural presentations of Alzheimer's disease among ethnic/racial groups...
  94. ncbi Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease
    Shirley W Y Tsang
    Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Singapore
    Neurobiol Aging 28:1381-7. 2007
    ....
  95. pmc Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease
    Shirley W Y Tsang
    Dementia Research Laboratory, Department of Clinical Research, Singapore General Hospital, Singapore
    Neurobiol Aging 29:1524-32. 2008
    ..We propose that NR2A and GlyRS should be further assessed as novel targets of behavioral pharmacotherapy in AD...
  96. ncbi ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
    Alzheimer Dis Assoc Disord 20:S139-46. 2006
    ....
  97. pmc The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families
    Jill Murrell
    Department of Pathology and Laboratory Medicine, University of Indiana Medical School, 635 Barnhill Drive, MS A128, Indianapolis, IN 46202 5126, USA
    Neurogenetics 7:277-9. 2006
    ....
  98. ncbi Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences
    Murat Emre
    Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey
    J Alzheimers Dis 11:509-19. 2007
    ..In both populations, hallucinations may identify patients who are likely to be more treatment-responsive...
  99. ncbi Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease
    Vorapun Senanarong
    Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Int Psychogeriatr 17:81-90. 2005
    ..Planning and judgment are involved in clock drawing. Neuropsychiatric symptoms are also mediated by frontal lobes, and a relationship between ADL, clock drawing and neuropsychiatric symptoms was hypothesized...
  100. ncbi Measuring disease modification in Alzheimer's disease
    Jeffrey L Cummings
    CNS Spectr 12:11-4. 2007
  101. ncbi The role of positron emission tomography in the diagnosis of Alzheimer's disease
    Jeffrey L Cummings
    J Am Geriatr Soc 52:467-8; author reply 468-9. 2004